Advertisement

Treatment of Motor Fluctuations in Parkinson’s Disease: Controlled Release Preparations

  • T. Caraceni
  • G. Geminiani
  • S. Genitrini
  • P. Giovannini
  • F. Girotti
  • D. Oliva
  • F. Tamma
Part of the Advances in Behavioral Biology book series (ABBI, volume 39)

Abstract

The fundamental problem in the treatment of Parkinson’s disease is the appearance of motor fluctuations after long-term drug therapy (long-term L-dopa treatment syndrome, LTS, Marsden and Parkes, 1976). The clinical manifestations of LTS are complex, consisting of a varying association of akinetic symptoms and dyskinesias whose pathogenesis has still not been clarified.

Keywords

Motor Fluctuation Control Release Form Target Symptom Dopaminergic Stimulation Slow Release Formulation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Cedarbaum, J. M., Breck, L., Kutt, H., and McDowell, F. H., 1987. Controlled release levodopa/carbidopa. Sinemet CR4 treatment of response fluctuations in Parkinson′s disease, Neurology, 37: 1607.PubMedCrossRefGoogle Scholar
  2. Chouza, C., Romero, S., Medina, 0. de, Aljanati, R., Scarmelli, A., Caamano, J. L., Panizza, V. G., 1987, Substitution of standard Madopar by Madopar HBS in Parkinsonians with fluctuations, Eur.Neurol., 27: suppl. 1, 59.Google Scholar
  3. Erni,W., and Held, K., 1987, The hydrodynamically Balanced System: a novel principle of controlled drug release, Eur. Neurol., 27: suppl. 1, 21.Google Scholar
  4. Friedman, J. H., and Lannon, M. C., 1989, An open trial of controlled release carbidopa/L-dopa (Sinemet CR) for the treatment of mild-to-moderate Parkinson's disease, Clinical. Neuropharmacol., 12: 220.CrossRefGoogle Scholar
  5. Friedman, J. H., and Lannon, M. C., 1989, An open trial of controlled release carbidopa/L-dopa (Sinemet CR) for the treatment of mild-to-moderate Parkinson's disease, Clinical. Neuropharmacol., 12: 220.CrossRefGoogle Scholar
  6. Hardie, R. J., Lees, A. J., and Stern, G. M., 1984, On-off fluctuations in Parkinson′s disease. A clinical and pharmacological study, Brain, 107: 487.PubMedCrossRefGoogle Scholar
  7. Hutton, J. T., Morris, J. L., Roman, G. C., Imke, S. C., and Elias, J. M., 1988, Treatment of chronic Parkinson's disease with controlled-release carbidopa/levodopa, Arch. Neurol., 45: 861.Google Scholar
  8. Jensen, N. O., Dupont, E., Hansen, E., Mikkelsen, B., and Mikkelsen, B. 0., 1988, A controlled release form of Madopar in Parkinsonian patients with advanced disease and marked fluctuations in motor performance, Acta Neurol. Scand., 77: 422.Google Scholar
  9. Junkos, J. L., Fabbrini, G., and Mouradian, M. M., 1987, Controlled release levodopa treatment of motor fluctuations in Parkinson′s disease, J. Neurol. Neurosurg. Psychiatry, 50: 194.CrossRefGoogle Scholar
  10. Lees, A. J., 1987, A sustained-release formulation of L-Dopa (Madopar HBS) in the treatment of nocturnal and early-morning disabilities in Parkinson′s disease, Eur. Neurol., 27: suppl. 1, 126.CrossRefGoogle Scholar
  11. Ludin, H. P., 1987, Open clinical study of Madopar HBS, Eur. Neurol., 27: supp1. 1, 73.CrossRefGoogle Scholar
  12. Malcom, S. L., Allen, J. G., Bird, H., Quinn, N. P., Marion, M. H., Marsden, C. D., O’Leary, C. G., 1987, Single-dose Pharmacokinetics of Madopar HBS in Patients and effect on food and antacid on the absorption of Madopar HBS in volunteers, Eur. Neurol., 27: suppl. 1, 28.CrossRefGoogle Scholar
  13. Marion, M. H., Stocchi, F., Malcom, S. L., Quinn, N. P., Jenner, P., and Marsden, C. D., 1987, Single dose studies of a slow release preparation of Levodopa and benserazide (Madopar HBS) in Parkinson′s disease, Eur. Neurol., 27: suppl.l, 54.CrossRefGoogle Scholar
  14. Marsden, C. D., and Parkes, J. D., 1976, On-off effects in patients with Parkinson′s disease on chronic levodopa therapy, Lancet, i: 292.Google Scholar
  15. Narabayashi, H., Yocochi, M., Iizuka, R., and Nagatsu, T., 1986, Juvenile parkinsoniam, in “Handbook of Clinical Neurology, Extrapyramidal Disorders”, P. J. Vinken and G. W. Bruyn, ed., Elsevier Science Publisher, Amsterdam.Google Scholar
  16. Nordera, G. P., Lorizio, A., Lion, P., Durisotti, C., D’Andrea, G., and Ferro-Milone, F., 1987, Treatment of parkinsonian conditions with a controlled release form of Levodopa - Preliminary study, Eur. Neurol., 27: suppl. 1, 76.CrossRefGoogle Scholar
  17. Obeso, J. A., Luquin, M. R., Martinez-Lage, J. M., 1983, Lisuride infusion in Parkinson′s disease, Ann. Neurol., 14: 134.CrossRefGoogle Scholar
  18. Quinn, N. P., Critchley, P., and Marsden, C. D., 1987, Young onset Parkinson′s disease, Movement Dis., 2, 2: 73.PubMedCrossRefGoogle Scholar
  19. Quinn, N. P., Marion, N. H., and Marsden, C. D., 1987, Open study of Madopar HBS, a new formulation of Levodopa with benserazide, in 13 patients with Parkinson′s disease and "on-off" fluctuations, Eur. Neurol., 27: suppl. 1, 105.Google Scholar
  20. Rinne, U. K., 1987, Madopar HBS in the long-term treatment of Parkinsonian patients with fluctuations in disability, Eur. Neurol., 27: suppl. 1, 120.CrossRefGoogle Scholar
  21. Rondot, P., Ziegler, M., Aymard, N., and Holzer, J., 1987, Clinical trial of Madopar HBS in Parkinsonian patients with fluctuating drug response after long-term levodopa therapy, Eur. Neurol., 27: suppl.l, 114.CrossRefGoogle Scholar
  22. Yokochi, M., 1979, Juvenile Parkinson's disease: Pt. 2. Pharmacokinetic study, Adv. Neurol. Sci., 23: 1060.Google Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • T. Caraceni
    • 1
  • G. Geminiani
    • 1
  • S. Genitrini
    • 1
  • P. Giovannini
    • 1
  • F. Girotti
    • 1
  • D. Oliva
    • 1
  • F. Tamma
    • 1
  1. 1.Istituto NeurologicoCentre for the Study of Parkinson’s Disease and Extrapyramidal DiseasesMilanItaly

Personalised recommendations